ClinicalTrials.gg
CompletedNCT05026996Updated Oct 9, 2024

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

A Phase 1 interventional study of Pelacarsen in Hepatic Impairment, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This was a Phase I, open-label, single-dose, parallel-group study in participants with mild hepatic impairment (HI) and healthy matched control participants with normal hepatic function designed to evaluate the PK of pelacarsen following a single 80 mg s.c. dose. Participants were matched by gender, age (±10 years), and body weight (±15%).

Read the detailed description

The study consisted of a Screening period of up to 28 days, followed by Baseline evaluations on Day -1. Participants who met the eligibility criteria at Screening were admitted to Baseline evaluations.

On Day 1, participants received a single s.c. injection of 80 mg pelacarsen followed by PK sampling up to Day 60 (±3 days). Participants were domiciled for at least 4 overnight stays (Day -1 through Day 4) for PK sample collection up to 72 hours postdose and were to return to the study site on 3 occasions (Days 8, 30 [±2 days], and 60 [±3 days]) for additional PK sample collection.

Study Completion evaluation occurred with the completion of Day 60 (±3 days) assessments. The total study duration for each participant was expected to be up to a maximum of 89 (±3) days, including the Screening period.

A post study safety contact took place on Day 112, approximately 16 weeks after dosing.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • CTQJ230
  • Hepatic Impairment
  • Subcutaneous injection
  • single-dose
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants

  1. Signed must be obtained prior to participation in the study.
  2. Male and non-child bearing potential female participants, 18 to 75 years of age (inclusive), at Screening.
  3. Participants must weigh at least 50 kg to participate in the study, and must have a within the range of 18.0 - 38.0 kg/m2, at Screening.
  4. Ability to communicate well with the investigator, to understand and comply with the requirements of the study.
  5. Must be a non-smoker or agree to smoke no more than 5 cigarettes (or equivalent) per day from Screening until Study Completion.

    Participants with mild HI (Group 2)

  6. Participants must have a prior diagnosis of liver cirrhosis and mild HI as defined by the classification with a score of 5-6, inclusive (Class A)
  7. Participants have been clinically stable and had no worsening of more than 1 point in Child Pugh score within 1 month prior to dosing of study treatment.
  8. Seated vital signs must be within the following ranges at Screening and Baseline:

    • Body temperature between 35.0 to 37.5°C, inclusive;
    • Systolic blood pressure between 100 to 159 mmHg, inclusive;
    • Diastolic blood pressure between 60 to 109 mmHg, inclusive;
    • Pulse rate between 45 - 99 bpm, inclusive.
  9. Participants with other stable medical disorders such as controlled diabetes, hyperlipidemia, hypothyroidism, etc., may be eligible as long as they are considered appropriate for enrollment as determined by the investigator by medical history, physical examination, , and clinical laboratory tests at Screening.

    Healthy control participants (Group 1)

  10. Each participant must match 1:1 in gender, age (± 10 years), and body weight (± 15%) to a participant with mild HI.
  11. Seated vital signs must be within the following ranges at Screening and Baseline:

    • Body temperature between 35.0 to 37.5°C, inclusive;
    • Systolic blood pressure between 89 to 139 mmHg, inclusive;
    • Diastolic blood pressure between 50 to 89 mmHg, inclusive;
    • Pulse rate between 45 to 90 bpm, inclusive.
  12. Participants must be in good health as determined by medical history, physical examination, ECG, and clinical laboratory tests at Screening.

Exclusion criteria

Exclusion Criteria:

All participants

  1. Use of other drugs within 5 half-lives or 30 days prior to dosing of study treatment, whichever is longer.
  2. History of to the study treatment or its or to drugs of similar chemical classes.
  3. Treatment with any oligonucleotide (with an exception for COVID 19 vaccines) or SiRNA within 9 months prior to Screening.
  4. Participants who received any COVID 19 vaccination and/or have not completed their full COVID-19 vaccination regimen within 14 days prior to Screening.
  5. Women of child bearing potential, defined as all women physiologically capable of becoming pregnant. Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks prior to the first dosing. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential.
  6. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 16 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above.
  7. Known history of, or current arrhythmias, history of prolonged corrected by Fridericia's formula (QTcF), QTcF > 450 msec (males), or QTcF > 460 msec (females) at Screening.
  8. History of immunodeficiency diseases or have a positive test result at Screening.
  9. History of of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years of Screening, regardless of whether there is evidence of local recurrence or .
  10. Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing of study treatment.
  11. count ≤ LLN at Screening or Baseline.
  12. History of unhealthy alcohol use within 12 months prior to dosing of study treatment, as defined by a recurring pattern of either binge drinking (≥ 5 drinks over 2 3 hours on ≥ 5 days/month) or heavy drinking (≥ 8 drinks/week in females or > 15 drinks/week in males). A "drink" definition includes: 12 ounces of 5% beer, 8 ounces of 7% malt liquor, 5 ounces of 12% wine or 1.5 ounces of 40% spirits.
  13. Positive alcohol screen at Screening or Baseline.
  14. History of drug abuse within the last 12 months or evidence of such abuse as indicated by the laboratory assay conducted during Screening or Baseline, unless the positive drug screen is due to prescription drug use that is approved by the investigator and Novartis.
  15. Clinically significant illness (other than HI for participants in Group 2) within 2 weeks prior to dosing of study treatment that may jeopardize safety of the participant and/or alter the study results as judged by the investigator.
  16. Significant glomerular disease (including but not limited to IgA nephropathy, diabetic nephropathy, systemic lupus erythematosus, etc.) with urinary protein-creatinine ratio > 500 mg/g (56.6 mg/mmol).
  17. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs (apart from cholecystectomy), or which may jeopardize the participants in case of participation in the study. The investigator should make this determination in consideration of the participant's medical history.
  18. Have tattoo(s) or scarring at or near the site of injection or any other condition which may interfere with injection site examination, in the opinion of the investigator.
  19. Unwillingness or inability (e.g. physical or cognitive) to comply with study procedures, study treatment administration (i.e. injection), or schedule.

    Participants with mild HI (Group 2)

  20. Presence of any non controlled and clinically significant disease that could affect the study outcome or that would place the participant at undue risk.
  21. Severe complications of liver disease within the preceding 3 months of Screening.
  22. Have received liver transplant at any time in the past.
  23. Participants requiring paracentesis more than every 30 days for the management of ascites. Participants who are receiving diuretics to manage ascites may be enrolled and will be assigned the score for the degree of ascites while on diuretic treatment. The diuretic dose must have been stable for at least 14 days prior to dosing of study treatment.
  24. Have transjugular intrahepatic portosystemic shunt and/or have undergone portacaval shunting.
  25. Have acute or C infection at Screening or active infection requiring therapy that will not be completed before Screening.
  26. Presence of moderate to severe impaired renal function as indicated by estimated \< 45 mL/min/1.73 m2 based on MDRD calculation.
  27. levels below 10.0 g/dL at Screening or Baseline.
  28. Have encephalopathy Grade 3 or worse within 28 days prior to dosing of study treatment.
  29. Have primary biliary cholangitis or biliary obstruction.
  30. History of gastrointestinal bleeding within the past 3 months prior to Screening.
  31. Clinically significant abnormal findings in physical examination or clinical laboratory evaluations not consistent with known liver disease.

    Healthy control participants (Group 1)

  32. Any single parameter of (ALT), aspartate aminotransferase (AST), gamma glutamyl-transferase (GGT), or alkaline phosphatase (ALP) exceeding 1.2 x (ULN), total ≥ 1.5 x ULN, or any elevation above ULN of more than one parameter of ALT, AST, GGT, ALP, or total bilirubin at Screening or Baseline.
  33. Hemoglobin levels more than 10% below LLN at Screening or Baseline.
  34. Participants known to have Gilbert's syndrome.
  35. Chronic hepatitis B or infection. A positive HBsAg test, or if standard local practice, a positive hepatitis B virus core antigen test, is an exclusion. Participants with a positive hepatitis C virus (HCV) antibodies (Ab) test should have HCV ribonucleic acid (RNA) levels measured. Participants with positive (detectable) HCV RNA should be excluded.
  36. Are taking medications prohibited with the study treatment (see Section 6.2.2 for additional details on prohibited medication) or herbal supplements, prescribed medicinal use of cannabis/marijuana, within 14 days prior to dosing of study treatment.
  37. Impaired renal function as indicated by clinically significantly abnormal creatinine or blood urea nitrogen and/or urea values, or abnormal urinary constituents at screening and/or baseline.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment patients

    Participants with mild hepatic impairment

    Drug: Pelacarsen

  • Experimental
    Healthy participants

    Matched healthy participants with normal hepatic function

    Drug: Pelacarsen

Interventions

  • Single subcutaneous injection of pelacarsen

    Also known as: TQJ230

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters of pelacarsen: Cmax

    The maximum (peak) observed drug concentration in after single-dose administration (mass x volume-1). To assess the PK properties of plasma pelacarsen after a single s.c. injection in participants with mild HI (Child-Pugh classification) as compared to matched healthy participants with normal hepatic function.

    Time frame: Day 1 (0 hour (pre-dose) 0.5 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour), Day 2, Day 3, Day 4, Day 8, Day 30 and Day 60

  2. Pharmacokinetic parameters of pelacarsen: AUClast

    The area under the concentration-time curve (AUC) from time zero to the last measurable concentration sampling time (mass x time x volume-1). To assess the PK properties of plasma pelacarsen after a single s.c. injection in participants with mild HI (Child-Pugh classification) as compared to matched healthy participants with normal hepatic function.

    Time frame: Day 1 (0 hour (pre-dose) 0.5 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour), Day 2, Day 3, Day 4, Day 8, Day 30 and Day 60

  3. Pharmacokinetic parameters of pelacarsen: AUCinf

    The AUC from time zero to infinity (mass x time x volume-1). To assess the PK properties of plasma pelacarsen after a single s.c. injection in participants with mild HI (Child-Pugh classification) as compared to matched healthy participants with normal hepatic function.

    Time frame: Day 1 (0 hour (pre-dose) 0.5 hour, 1 hour, 1.5 hour, 2 hour, 3 hour, 4 hour, 6 hour, 8 hour, 12 hour), Day 2, Day 3, Day 4, Day 8, Day 30 and Day 60

07

Study locations

1 site
  • Novartis Investigative Site
    San Antonio, Texas 78215, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Oct 2022, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Aug 30, 2021
StartActual
Nov 23, 2021
Primary completionActual
Oct 19, 2022
CompletionActual
Oct 19, 2022
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05026996
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Nov 23, 2021
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022
Last update
Oct 9, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pelacarsen

Start the discussion